| Patent application number | Description | Published |
|---|
| 20140114987 | SYSTEMS AND METHODS FOR QUANTIFYING THE IMPACT OF BIOLOGICAL PERTURBATIONS - Systems and methods are described for quantifying the response of a biological system to one or more perturbations. First and second datasets corresponding to a response of a biological system to first and second treatments are received. A plurality of computational network models that represent the biological system are provided, each model including nodes representing a plurality of biological entities and edges representing relationships between the nodes in the model. A first set of scores is generated, representing the perturbation of the biological system based on the first dataset and the plurality of models, and a second set of scores representing the perturbation of the biological system based on the second dataset and the plurality of computational models. One or more biological impact factors are generated based on each of the first set and second set of scores that represent the biological impact of the perturbation on the biological system. | 04-24-2014 |
| 20140172398 | SYSTEMS AND METHODS FOR NETWORK-BASED BIOLOGICAL ASSESSMENT - Systems and methods are directed to computerized methods and one or more computer processors for quantifying the perturbation of a biological system in response to an agent. A set of treatment data corresponding to a response of a biological system to an agent and a set of control data are received. A computational causal network model represents the biological system and includes nodes representing biological entities, edges representing relationships between the biological entities, and direction values representing the expected direction of change between the control data and the treatment data. Activity measures are calculated and represent a difference between the treatment data and the control data, and weight values are calculated for the nodes. A score for the computational model is generated representative of the perturbation of the biological system to the agent and is based on the direction values, the weight values and the activity measures. | 06-19-2014 |
| 20140207385 | SYSTEMS AND METHODS FOR CHARACTERIZING TOPOLOGICAL NETWORK PERTURBATIONS - Systems, computerized methods and products are disclosed herein for determining metrics for nodes in a network model of a biological system. Such systems and computerized methods can be used to quantify the response of a biological system to one or more perturbations based on measured activity data of a subset of entities in the biological system. Based on the activity data and a network model of the biological system, centrality values representative of the relative importance of a node in the network are derived. The centrality values are used for characterizing topological perturbations in the network, such as for performing sensitivity analysis, visualizing topological effects of a perturbation in the biological system, or deriving a score quantifying the response of the biological system to a perturbation such as exposure to a chemical agent. | 07-24-2014 |
| 20140214336 | SYSTEMS AND METHODS FOR NETWORK-BASED BIOLOGICAL ACTIVITY ASSESSMENT - Systems and methods are disclosed herein for quantifying the response of a biological system to one or more perturbations based on measured activity data from a subset of the entities in the biological system. Based on the activity data and a network model of the biological system that describes the relationships between measured and non-measured entities, activities of entities that are not measured are inferred. The inferred activities are used for deriving a score quantifying the response of the biological system to a perturbation such as a response to a treatment condition. The score may be representative of the magnitude and topological distribution of the response of the network to the perturbation. | 07-31-2014 |
| 20140352706 | ISOPROPYLMALATE SYNTHASE FROM NICOTIANA TABACUM AND METHODS AND USES THEREOF - The present invention relates to a mutant, non-naturally occurring or transgenic plant cell comprising: (i) at least one polynucleotide comprising, consisting or consisting essentially of a sequence encoding an isopropylmalate synthase and having at least 60% sequence identity to SEQ ID NO:1 or SEQ ID NO:10 or SEQ ID NO: 12 or SEQ ID NO:14; or (ii) a polypeptide encoded by said polynucleotide(s); or (iii) a polypeptide having at least 60% sequence identity to SEQ ID NO:2 or SEQ ID NO:11 or SEQ ID NO:13 or SEQ ID NO:15; or (iv) a construct, vector or expression vector comprising said polynucleotide sequence(s), optionally wherein said construct, vector or expression vector additionally comprises a promoter comprising, consisting or consisting essentially of the sequence set forth in SEQ ID NO:8 or a variant thereof with at least about 60% identity thereto or a trichome promoter. | 12-04-2014 |
| 20150154353 | SYSTEMS AND METHODS FOR GENERATING BIOMARKER SIGNATURES WITH INTEGRATED DUAL ENSEMBLE AND GENERALIZED SIMULATED ANNEALING TECHNIQUES - Described herein are systems and methods for classifying a data set using an ensemble classification technique. Classifiers are iteratively generated by applying machine learning techniques to a training data set, and training class sets are generated by classifying the elements in the training data set according to the classifiers. Objective values are computed based on the training class sets, and objective values associated with different classifiers are compared until a desired number of iterations is reached, and a final training class set is output. | 06-04-2015 |
| 20150178639 | SYSTEMS AND METHODS FOR GENERATING BIOMARKER SIGNATURES WITH INTEGRATED BIAS CORRECTION AND CLASS PREDICTION - Described herein are systems and methods for correcting a data set and classifying the data set in an integrated manner. A training data set, a training class set, and a test data set are received. A first classifier is generated for the training data set by applying a machine learning technique to the training data set and the training class set, and a first test class set is generated by classifying the elements in the test data set according to the first classifier. For each of multiple iterations, the training data set is transformed, the test data set is transformed, and a second classifier is generated by applying a machine learning technique to the transformed training data set. A second test class set is generated according to the second classifier, and the first test class set is compared to the second test class set. | 06-25-2015 |
| 20150220838 | SYSTEMS AND METHODS RELATING TO NETWORK-BASED BIOMARKER SIGNATURES - Systems and methods are provided herein for generating a classifier for phenotypic prediction. A computational causal network model representing a biological system includes a plurality of nodes and a plurality of edges connecting pairs of nodes. A first set of data corresponding to activities of a first subset of biological entities obtained under a first set of conditions is received, and a second set of data corresponding to activities of the first subset of biological entities obtained under a second set of conditions is received. A set of activity measures representing a difference between the first and second sets of data for a first subset of nodes is calculated. A set of activity values for a second subset of nodes, which are unmeasured, is generated. A classifier is generated for the phenotypes based on the set of activity measures, the set of activity values, or both. | 08-06-2015 |
| 20150294218 | Quantitative assessment of biological impact using mechanistic network models - A method to score a causally consistent network is provided by transforming the network into a hypothesis subnetwork, called a “HYP” (if the nodes have associated measurements) or a “meta-HYP” (if the nodes are themselves HYPs), and then applying known HYP scoring methods (e.g. (NPA, GPI, or the like) based on measurements or scores associated with nodes in the subnetwork. A method also is described for creating a HYP or meta-HYP with weights associated with each downstream node from a causally inconsistent network using a computational technique such as sampling of spanning trees. A further aspect is a method to transform a meta-HYP (with or without weights associated with each downstream node) into a HYP using the weights associated with each downstream node (where the weights are based on the scoring algorithms intended at the meta-HYP and HYP levels). | 10-15-2015 |
| Patent application number | Description | Published |
|---|
| 20110110904 | NUTRITIONAL COMPOSITION CONTAINING OLIGOSACCHARIDE MIXTURE - A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligosaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life. | 05-12-2011 |
| 20130224331 | NUTRITIONAL COMPOSITION CONTAINING OLIGOSACCHARIDE MIXTURE - A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligasaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto- oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosacchardide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life. | 08-29-2013 |
| 20150030720 | NUTRITIONAL COMPOSITION CONTAINING OLIGOSACCHARIDE MIXTURE - A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligosaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life. | 01-29-2015 |
| Patent application number | Description | Published |
|---|
| 20140073526 | IMMUNE FUNCTION BIOMARKERS - The invention provides biomarkers associated with age related immune function and the use of the biomarkers to identify compositions useful for strengthening immune function in animals and to determine if an animal is responding to treatment targeted to strengthen the immune system. | 03-13-2014 |
| 20150072043 | 9-OXO-HODE AS A BIOMARKER FOR HEALTHY AGING - Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-HODE as biomarker. | 03-12-2015 |
| 20150072320 | PC-O 40:1 AS A BIOMARKER FOR HEALTHY AGING - Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using PC—O 40:1 as biomarker. | 03-12-2015 |
| 20150072363 | PHENYLACETYLGLUTAMINE AS A BIOMARKER FOR HEALTHY AGING - Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose an in vitro method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using phenylacetylglutamine (PAG) as biomarker. | 03-12-2015 |
| 20150075262 | PC-O 44:4 - A BIOMARKER FOR VISCERAL ADIPOSITY - The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject. | 03-19-2015 |
| 20150080264 | PC-O 44:6 - A BIOMARKER FOR VISCERAL ADIPOSITY - The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:6 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject. | 03-19-2015 |
| 20150096357 | PC-O 42:4 - A BIOMARKER FOR VISCERAL ADIPOSITY - The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 42:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject. | 04-09-2015 |
| 20150105296 | HYDROXY-SPHINGOMYELIN 22:1 AS A BIOMARKER FOR HEALTHY AGING - Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker. | 04-16-2015 |
| 20150147817 | PC-O 44:4 - A BIOMARKER FOR VISCERAL ADIPOSITY - The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:4 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject. | 05-28-2015 |
| 20150160191 | FUCOSE AS A BIOMARKER FOR GUT IMMUNITY - The present invention generally relates to the field of biomarkers. For example, the present invention relates to biomarkers that can be used to assess the likelihood of having the FUT2 secretor genotype in a subject. The invention also relates to biomarkers that can be used to assess gut health. Fucose was identified as biomarker that can be used for these purposes. | 06-11-2015 |
| 20150174080 | NUTRITIONAL COMPOSITION FOR PROMOTING MUSCULOSKELETAL HEALTH IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) - A nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease is disclosed. The nutritional composition comprises casein protein, vitamin K in a ratio of vitamin K1:vitamin K2 being between 3:1 to 1:3 and the vitamin K providing between 3.5-20 μg/100 kcal of the nutritional composition, vitamin D and alpha-linolenic acid. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed. | 06-25-2015 |
| 20150309051 | ISOVALERYLGLYCINE AS BIOMARKER FOR THE PREDISPOSITON FOR WEIGHT GAIN AND OBESITY - The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be isovalerylglycine. | 10-29-2015 |
| Patent application number | Description | Published |
|---|
| 20090237335 | DISPLAY DEVICE ABLE TO OPERATE IN LOW POWER PARTIAL DISPLAY MODE - The display device includes a display cell including liquid crystals and a matrix of electrodes arranged in lines and columns in a closed cavity. The lines and columns define display cell pixels. The display device includes a control circuit for lines and columns for display of data on the display cell. In complete display mode, all lines and columns are addressed at several voltage levels by successive line-by-line multiplexing. In low power partial display mode, two groups of adjacent lines are joined so they are each controlled by a respective line control signal from the control circuit. The N lines and groups of lines are simultaneously addressed in active manner at two voltage levels. N line control signals include a series of N-bit binary line words that change every determined period of time, T, so 2 | 09-24-2009 |
| 20130107677 | CIRCUIT FOR AUTOREGULATING THE OSCILLATION FREQUENCY OF AN OSCILLATING MECHANICAL SYSTEM AND DEVICE INCLUDING THE SAME | 05-02-2013 |
| 20130163395 | WATERPROOF WATCH PUSHBUTTON - Sealed pushbutton for a wristwatch comprising a pushbutton head that is movable between a resting position and an active position, a first fixed conductive element and a second movable conductive element. It comprises an elastically deformable capsule that hermetically covers the first fixed conductor, wherein an upper surface of the capsule is in physical contact with a lower surface of the pushbutton head. The capsule can be located in a non-deformed position when the pushbutton head is in its resting position and in a deformed position when the pushbutton head is in its active position, and the first and second conductive elements form a capacitive or resistive switch device, wherein the switch is in open state when the pushbutton head is in its resting position and in closed state when the pushbutton head is in its active position. | 06-27-2013 |
| 20140230525 | ELECTRONIC DEVICE PROVIDED WITH AUTOMATIC LEAK DETECTION MEANS - The electronic device is provided with an automatic leak detection means, notably for a gas leak, in the case of the device. The automatic leak detection means includes a pressure sensor, a temperature sensor and a calculation unit connected to the pressure sensor and to the temperature sensor. The calculation unit, which is a microcontroller, the pressure sensor and the temperature sensor are arranged inside the case. In operation, the microcontroller checks, based on measurements performed by the pressure sensor and the temperature sensor over time, whether the variation in pressure in the case is within a defined margin proportional to the variation in temperature to determine whether or not the case has a sufficient degree of sealing. | 08-21-2014 |
| 20140230526 | ELECTRONIC DEVICE PROVIDED WITH AUTOMATIC LEAK DETECTION MEANS - The electronic device ( | 08-21-2014 |
| 20150180080 | BATTERY WITH STRUCTURED SURFACE - The present invention concerns a battery including an anode case, an anode situated inside the anode case, a cathode case fixed to the anode case, a seal sealing the cathode case to the anode case, a cathode situated inside the cathode case between the anode and the cathode case, and a membrane between the anode and the cathode, said battery being characterized in that one outer surface of said accumulator includes at least one marking created by local heating of material, said marking being electrically conductive. | 06-25-2015 |
| 20150224813 | WRITING INSTRUMENT - A protective element for a writing tip of a writing instrument including a cap extending longitudinally along a central axis and configured to be fitted onto a body of the instrument, and a clip extending substantially parallel to the central axis from a first end fixed to the cap to a free end. The clip and the cap are in one piece. | 08-13-2015 |
| 20150231915 | WRITING INSTRUMENT - A writing instrument including: a body extending longitudinally along a central axis; a resilient element fixed to at least one portion of the body. The resilient element of the at least one portion of the body is in one piece and is made of at least partially amorphous metal alloy. | 08-20-2015 |
| 20150241848 | ILLUMINATION OF A DATE MECHANISM - A device for illuminating at least one display indicator incorporated in a case underneath an aperture of a horological or scientific apparatus, the device including a phosphorescent light source inside the case, a mechanism collecting external light energy from an ambient medium of the case towards the phosphorescent light source, and at least one light component formed, either by the source, or by a light relay connected to the source by a transmission mechanism, and the light component is configured, to illuminate the indicator, either on the opposite side to the aperture relative to the indicator, or at a periphery of the aperture, and a controller is configured to move a cover insertable between the light component and the indicator. | 08-27-2015 |
| 20150261187 | ILLUMINATED BALANCE SPRING - A watch or timepiece regulating member includes a balance, a balance-cock, at least one light energy source, and at least one balance spring attached between the balance and the balance-cock. The balance spring is made of quartz or of glass or of ceramic or is partially transparent to visible and/or ultraviolet wavelengths or made of an at least partially amorphous material and transmits and diffuses light emitted by the light energy source. | 09-17-2015 |
| 20150261188 | ILLUMINATED TIMEPIECE DISPLAY DEVICE - A watch including a mechanical movement with a display device including a light energy source and a slender, elastic, mobile component that is deformable during operation, or a balance spring, at least partially transparent, which transmits and diffuses light that varies with stress in the elastic and deformable portion. The light source is active or passive and injects light into one portion of the mobile component which conveys and diffuses light over at least one portion of the mobile component, or throughout the entire mobile component, to make it visible in the dark. | 09-17-2015 |
| Patent application number | Description | Published |
|---|
| 20130339246 | SECURITY SYSTEM - An apparatus for processing documents and/or tokens of monetary value, operable locally or remotely via an application used on device. The apparatus has a record of a security certificate of the application, and a receiver which receives a request for an identification code from the device, the request being signed by the application used on the device. The receiver verifies the device as an approved device if the signed request is recognised based on the record of the security certificate. The apparatus generates an identification code, stores the identification code, and sends the identification code to the approved device. The apparatus is configured to receive a command from the application used on the approved device, which command utilises the identification code. The apparatus is further configured to compare the identification code utilised in the command with the stored identification code, and execute the command if they match. | 12-19-2013 |
| 20140297526 | Cash and/or Financial Document Handling System - A controller comprising: a database; a control module associated with the database; and a network interface configured to connect, over a network, to a plurality of workstations and at least one machine for performing operations to handle cash and/or other physical financial documents. The network interface receives requests from at least some of the workstations over the network, each comprising a request to pre-order a respective one of the operations. The requests are stored in the database. The network further receives, over the network, a signal from or on behalf of a slave module of the machine for retrieving one of the requests from the database. The control module processes the signal and in response releases the respective operation, the release comprising issuing an instruction to the slave module over the network controlling the machine to perform the respective operation to handle the cash and/or other physical financial document. | 10-02-2014 |
| Patent application number | Description | Published |
|---|
| 20140222672 | System And Method For Validating A Controller For An Automated Banking Machine Using A Displayed Indicia - A computer implemented method for validating the identity of a controller for an automated banking machine based on displayed indicia. The method includes detecting access to a secure compartment of an automated banking machine, displaying a security indicia visible from the secure compartment, receiving the security indicia at an input device and a first controller accessible from outside of the secure compartment, and validating the identity of the controller based on the received security indicia. | 08-07-2014 |
| 20140222673 | System and Method for Communicating Financial Transactions Using a Tagless Data Interchange Format - An automated banking a machine such as a teller cash recycler uses a system and method for receiving operating instructions from a remote system in the form of JavaScript object notation (JSON) documents. The system and method uses a computer implemented method for transmitting information between automated banking machines over a communication network. The method includes receiving a message for network communication from a first automated banking machine to a second automated banking machine, formatting the message in a tagless data interchange format independent of the size of the message based on instructions stored on a computer readable medium within the first automated banking machine, and transmitting the formatted message to the second automated banking machine. | 08-07-2014 |
| 20140304693 | System And Method For Updating Configuration Data For Sub-Systems Of An Automated Banking Machine - A computer implemented method for updating configuration data in at least one automated banking machine is configured to execute configuration update steps embodied with a computer readable medium. The method includes identifying one or more sub-systems implemented within the automated banking machine, receiving an update to configuration data for at least one of the identified sub-systems, generating a restore point based on a current implementation of the sub-systems for the automated banking machine, and installing the configuration data in the automated banking machine. The identified sub-systems can include at least two of roll storage modules, a note handling module controller, a note detector module, and an interface controller. | 10-09-2014 |
| Patent application number | Description | Published |
|---|
| 20080242857 | Process For Preparing Porphyrin Derivatives, Such As Protoporphyrin (IX) And Synthesis Intermediates - The present invention relates to a process for preparing a porphyrin of formula (I), optionally in the form of a salt with an alkali metal and/or in the form of a metal complex: | 10-02-2008 |
| 20090118512 | Process for Preparing 6,7-Dihydro-5H-Imidazo[1,5-A]Pyridin-8-One - 6,7-Dihydro-5H-imidazo[1,5-a]pyridin-8-one (I), is obtainable in high yields by: 1) a process which proceeds from a suitably protected C-(3-hydroxypyridin-2-yl)methylamine whose amine is converted to the formamide which is then cyclized to the imidazo[1,5-a]pyridine and hydrogenated to the 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one, and suitably protected C-(3-hydroxypyridin-2-yl)methylamines can be prepared either in 2 steps proceeding from commercially available 3-hydroxy-2-cyanopyridine [932-35-4] or in 3 steps proceeding from commercially available 2-hydroxymethylpyridin-3-ol [14173-30-9]; 2) a process for preparing 4-hydroxy-1-(1H-imidazol-4-yl)butan-1-one, an intermediate from the synthesis of 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one (formula I), as described in WO 2002/040484, proceeding from N,N-dimethyl-2-(trialkylsilanyl)imidazole-1-sulphonamide by lithiation and subsequent reaction with a suitably protected 4-hydroxybutyraldehyde, followed by oxidation of the secondary alcohol, acid-induced deprotection of the imidazole and deprotection of the alcohol functionality; 3) a process which proceeds from 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine [38666-30-7], which is oxidized. | 05-07-2009 |
| 20090148407 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication - The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-11-2009 |
| 20090155209 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 06-18-2009 |
| 20090169510 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 07-02-2009 |
| 20110306761 | Process For Preparing Prophyrin Derivatives, Such As Protoprophyrin (IX) And Synthesis Intermediates - The present invention relates to a process for preparing a porphyrin of formula (I), optionally in the form of a salt with an alkali metal and/or in the form of a metal complex: | 12-15-2011 |
| 20120208995 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 08-16-2012 |
| Patent application number | Description | Published |
|---|
| 20140212445 | USE OF MODIFIED CELLS FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis. | 07-31-2014 |
| 20140356320 | POLYOMA VIRUS JC PEPTIDES AND PROTEINS IN VACCINATION AND DIAGNOSTIC APPLICATIONS - The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof. | 12-04-2014 |
| 20150157651 | TRI-SUBSTITUTED GLYCEROL COMPOUNDS FOR USE IN THE TREATMENT OF CLINICALLY ISOLATED SYNDROME AND/OR MULTIPLE SCLEROSIS - The present invention relates to tri-substituted glycerol compounds according to formula (I) as described herein for use in the treatment of clinically isolated syndrome, relapsing remitting multiple sclerosis (RR-MS) and/or secondary progressive multiple sclerosis (SP-MS). The tri-substituted glycerol compounds according to formula (I) as described herein may also be used for the treatment of multiple sclerosis patients not adequately responding to interferon therapy. The present invention also relates to a tri-substituted glycerol compound as described herein, for use as a medicament, wherein the tri-substituted glycerol compound is administered in combination with at least one further pharmaceutically active compound. | 06-11-2015 |
